Related Experiment Video
Updated: Feb 27, 2026

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
Published on: May 26, 2023
Prothrombin Complex Concentrates in Pediatric Cardiac Surgery: The Current State and the Future
Elena Ashikhmina1, Sameh Said2, Mark M Smith1
1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.
Insights
Prothrombin complex concentrates (PCCs) show promise for treating bleeding in pediatric cardiac surgery, but more research is needed to establish safe and effective use in children. Current evidence is anecdotal, highlighting the need for studies on dosing and monitoring.
Area of Science:
- Pediatric Cardiac Surgery
- Hemostasis and Coagulation
- Pharmacology
Background:
- Postoperative bleeding is a persistent concern in pediatric cardiac surgery due to immature hemostasis, hemodilution, and hypothermia.
- Prothrombin complex concentrates (PCCs), used off-label in adults for post-bypass hemorrhage, offer potential benefits for pediatric patients.
- Optimal use, including dosing and monitoring, of PCCs in children remains undefined.
Purpose of the Study:
- To review the challenges of bypass-related coagulopathy in pediatric cardiac surgery.
- To outline the pharmacology and existing experience with PCCs.
- To explore the potential application of PCCs in pediatric cardiac surgery.
Main Methods:
- A comprehensive literature search was conducted across MEDLINE, Scopus, and Ovid databases.
- The search term used was "prothrombin complex concentrate AND pediatric."
- Twenty-three relevant articles were selected for review.
Main Results:
- While PCCs demonstrate attractive qualities for pediatric use (small volume, low immunogenicity, rapid action), current evidence is anecdotal.
- Key concerns include undefined dosing regimens and the lack of real-time monitoring capabilities.
- Potential thrombotic complications pose a significant risk, especially in pediatric patients reliant on artificial shunts.
Conclusions:
- Extensive, high-quality research is essential to address the knowledge gaps concerning PCC use in pediatric cardiac surgery.
- Further investigation is required to establish safe and effective protocols for PCC administration in this population.
Background:
After decades of practice of pediatric cardiac surgery, postoperative bleeding due to the immaturity of hemostasis, hemodilution, and hypothermia remains a concern. Recently, a new approach for adult coagulopathy after bypass has emerged. Prothrombin complex concentrates (PCCs), designed to treat bleeding in hemophilia patients, are safely and efficiently used off label for hemorrhage after bypass. However, optimal dosing, indications and contraindications, and laboratory tests to assess the efficacy of PCC use in children have not yet been established. This literature review outlines the challenges of bypass-related coagulopathy, the pharmacology, and the experience in use of PCCs, with a focus on their potential in pediatric cardiac surgery.
Methods:
After a thorough literature search of MEDLINE, Scopus, and Ovid databases using the term "prothrombin complex concentrate AND pediatric," 23 relevant articles were selected.
Results:
The data supporting successful use of PCCs in acquired coagulopathy after cardiac surgery in adults have been increasing. Although small volume, low immunogenicity, efficiency, and speed in correcting coagulopathy are attractive qualities of PCCs for pediatric practice, current evidence is only anecdotal. The main concerns are unknown dosing regimens, the inability to closely monitor the effects of PCCs in real time, and a possibility of thrombotic complications, which can be particularly devastating in young congenital cardiac patients whose lives frequently depend upon the patency of artificial shunts.
Conclusions:
Extensive, high-quality research is warranted to fill in the gaps of knowledge regarding using PCCs in pediatric cardiac practice.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Cardiac Catheterization I: Pre-Procedure Overview
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Cardiac Catheterization IV: Nursing Management

